```html

Iritis (Anterior Uveitis) – A Complete Patient Guide

Overview

Iritis, also called anterior uveitis, is inflammation of the iris—the colored part of the eye— and the adjoining tissue called the ciliary body. It is the most common form of uveitis, accounting for roughly 50‑70% of all uveitis cases. The condition can affect anyone, but it is most frequently diagnosed in adults between the ages of 20 and 50, with a slight male predominance.

Worldwide, uveitis (including iritis) is responsible for about 10–15 cases per 100,000 people each year. In the United States, an estimated 30,000–50,000 new cases of iritis are reported annually.

Symptoms

Symptoms can appear suddenly (acute iritis) or develop slowly (chronic). Common signs include:

• Eye pain: often described as a deep, aching pain that worsens with bright light (photophobia).
• Redness: the eye may appear blood‑shot, usually around the white part (sclera) near the iris.
• Blurred vision: vision can become hazy or “foggy.”
• Photophobia: heightened sensitivity to light; patients may squat or close their eyes in bright environments.
• Pupil changes: the affected pupil often becomes smaller (miosis) and reacts sluggishly to light.
• Floaters: specks or cobweb‑like shapes drifting in the visual field, caused by inflammatory cells in the vitreous.
• Headache: especially around the brow or temple, sometimes mistaken for sinus pain.
• Tearing or discharge: mild tearing is common; purulent discharge is unusual and may indicate infection.

Because symptoms overlap with other eye conditions (e.g., conjunctivitis, glaucoma), a professional eye exam is essential for accurate diagnosis.

Causes and Risk Factors

Underlying Causes

Iritis is rarely “idiopathic” (no known cause). Most cases are linked to one of the following:

• Autoimmune disorders: ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, and Behçet’s disease are frequently associated with recurrent iritis <sup>[1]</sup>.
• Infectious agents: herpes simplex virus (HSV), varicella‑zoster virus (VZV), cytomegalovirus (CMV), syphilis, tuberculosis, and Lyme disease can trigger inflammation.
• Systemic inflammatory diseases: sarcoidosis and inflammatory bowel disease (Crohn’s, ulcerative colitis).
• Trauma or surgery: penetrating eye injury or intra‑ocular surgery (e.g., cataract extraction) can initiate an inflammatory response.
• Medications: newer immunotherapies (e.g., checkpoint inhibitors) have been linked to uveitis in rare cases.

Risk Factors

• Age 20‑45 (peak incidence).
• Male sex (slightly higher risk).
• History of autoimmune disease.
• Prior episode of iritis or other uveitis.
• Genetic predisposition – HLA‑B27 positivity increases risk up to 30‑40% in affected individuals <sup>[2]</sup>.
• Living in areas with high rates of certain infections (e.g., TB, Lyme).

Diagnosis

Diagnosis is clinical and requires a comprehensive eye examination performed by an ophthalmologist or optometrist with slit‑lamp expertise.

Key Diagnostic Steps

1. Medical History: evaluation of systemic illnesses, recent infections, trauma, medication use, and prior eye problems.
2. Visual Acuity Test: baseline measurement of how well the patient can see.
3. Slit‑Lamp Examination: the gold standard; reveals:
   • Cellular infiltrates (flare) in the anterior chamber.
   • Pupil irregularities (e.g., posterior synechiae – adhesions between iris and lens).
   • Corneal involvement or keratic precipitates.
4. Intra‑ocular Pressure (IOP) Measurement: inflammation can cause either high or low pressure; important for treatment planning.
5. Fundus Examination: indirect ophthalmoscopy assesses posterior segment for complications.

Ancillary Tests (when indicated)

• Laboratory work‑up: CBC, ESR/CRP, HLA‑B27 typing, syphilis serology (RPR/VDRL), TB Quantiferon, Lyme serology, ANA, and rheumatoid factor depending on systemic clues.
• Imaging: chest X‑ray or CT for sarcoidosis; MRI of the brain/orbits if neurologic signs exist.
• Poncho‑Sying, Fluorescein Angiography: rarely required, reserved for posterior involvement.

Treatment Options

The primary goals are to control inflammation, prevent complications, and preserve vision.

Medications

• Topical Corticosteroids: prednisolone acetate 1% or difluprednate 0.05% drops are first‑line. Dose is tapered over weeks based on response. Side effects: raised IOP, cataract formation.
• Cycloplegic Agents: atropine or cyclopentolate to relieve pain, prevent synechiae, and keep the pupil dilated.
• Non‑steroidal Anti‑inflammatory Drugs (NSAIDs): topical ketorolac may be added for steroid‑sparing effect.
• Systemic Corticosteroids: oral prednisone (0.5‑1 mg/kg) for severe or bilateral cases, or when topical therapy fails.
• Immunomodulatory Therapy (IMT): for recurrent or chronic iritis, agents such as methotrexate, mycophenolate mofetil, azathioprine, or biologics (e.g., adalimumab) are used under rheumatology/ophthalmology supervision.
• Antiviral/Antibacterial Therapy: indicated when an infectious etiology is identified (e.g., acyclovir for HSV, oral doxycycline for Lyme).

Procedures

• Posterior Sub‑Tenon’s Steroid Injection: delivers a depot of corticosteroid in the posterior eye segment, useful for steroid‑responsive cases.
• Intravitreal Steroid Implant: fluocinolone or dexamethasone implants for chronic inflammation refractory to other therapy.
• Laser Iridotomy: rarely required but can relieve pupillary block if synechiae cause angle‑closure glaucoma.

Lifestyle & Supportive Measures

• Wear sunglasses with UV protection to minimize photophobia.
• Avoid smoking – it worsens autoimmune inflammation.
• Maintain regular follow‑up appointments (often weekly initially).
• Adhere strictly to medication schedule; missing drops can precipitate flare‑ups.

Living with Iritis

Managing iritis is a partnership between you and your healthcare team. Practical daily tips:

• Medication Diary: keep a log of eye drops, oral meds, and any side effects.
• Protect Your Eyes: use wide‑brimmed hats and sunglasses outdoors; avoid dusty or smoky environments.
• Rest the Eyes: follow the 20‑20‑20 rule (every 20 minutes, look at something 20 feet away for 20 seconds) to reduce strain.
• Monitor Vision Changes: note any new blurring, halos, or flashes and report them promptly.
• Manage Systemic Disease: if you have an autoimmune condition, keep it well‑controlled with your rheumatologist.
• Stay Hydrated and Eat Anti‑Inflammatory Foods: omega‑3 rich fish, leafy greens, and berries may have a modest beneficial effect.

Prevention

While not all cases are preventable, risk can be reduced:

• Control systemic inflammatory disorders with appropriate therapy.
• Promptly treat eye infections; avoid self‑medicating with over‑the‑counter steroid drops.
• Wear protective eyewear when engaging in activities with a risk of eye injury.
• Limit exposure to known triggers (e.g., avoid sudden bright‑light exposures if you have photophobia).
• Regular eye examinations for people with HLA‑B27 positivity or a history of uveitis.

Complications

If inflammation is not adequately controlled, several serious complications can develop, potentially leading to permanent vision loss:

• Glaucoma: elevated intra‑ocular pressure damages the optic nerve.
• Cataract Formation: especially posterior sub‑capsular cataracts from chronic steroid use.
• Posterior Synechiae: adhesions that can cause pupil distortion and secondary angle‑closure glaucoma.
• Macular Edema: swelling of the central retina leading to central vision loss.
• Band Keratopathy: calcium deposits on the cornea, causing visual haze.
• Permanent Vision Loss: rare but possible from uncontrolled inflammation or complications.

When to Seek Emergency Care

References

• [1] American Uveitis Society. Uveitis: Epidemiology and Classification. 2023. uveitis.org
• [2] Rosenbaum JT, et al. HLA‑B27–Associated Anterior Uveitis. Ophthalmology. 2022;129(4):456‑464.
• Mayo Clinic. Iritis (Anterior Uveitis). Updated 2024. mayoclinic.org
• Cleveland Clinic. Iritis – Symptoms, Diagnosis & Treatment. 2024. clevelandclinic.org
• CDC. Lyme Disease – Eye Complications. 2023. cdc.gov
• NIH National Eye Institute. Uveitis Overview. 2024. nei.nih.gov

```